Kiniksa Rule 144: 36,722 Class A Shares Listed

Kiniksa Pharmaceuticals Ltd. submitted a Rule 144 notice reporting proposed sale of Class A ordinary shares related to an Employee Stock Option Exercise dated 03/09/2026.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals Ltd. submitted a Rule 144 notice reporting proposed sale of Class A ordinary shares related to an Employee Stock Option Exercise dated 03/09/2026. The filing lists 36,722 shares in the securities-to-be-sold row and discloses prior sales by Mark Ragosa of 12,000 shares on 01/08/2026 and 17,845 shares on 02/09/2026, with corresponding proceeds of $502,628.00 and $772,311.00.

Insights

Insider Transactions Compliance Expert

Rule 144 notice documents proposed insider sale and recent disposals.

The filing lists 36,722 Class A ordinary shares tied to an Employee Stock Option Exercise dated 03/09/2026, filed under Rule 144. The method shown is a Broker Payment for Cashless Exercise, which typically converts option proceeds into share disposition at exercise.

Two prior sales by Mark Ragosa are reported: 12,000 shares on 01/08/2026 ($502,628.00) and 17,845 shares on 02/09/2026 ($772,311.00). Timing and cash‑flow recipients are explicit in the excerpt.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does KNSA's Form 144 filed on 03/09/2026 report?

The filing reports a proposed sale of Class A ordinary shares tied to an Employee Stock Option Exercise dated 03/09/2026, listing 36,722 shares to be sold.

Who sold shares for KNSA in the past three months according to the filing?

Mark Ragosa sold 12,000 shares on 01/08/2026 and 17,845 shares on 02/09/2026, as disclosed in the Form 144 excerpt.

What proceeds are shown for the recent Mark Ragosa sales in the KNSA filing?

The filing lists proceeds of $502,628.00 for the 12,000-share sale and $772,311.00 for the 17,845-share sale, with their respective dates.

What sale method is indicated for the securities-to-be-sold in the KNSA notice?

The securities-to-be-sold row indicates an Employee Stock Option Exercise with a Broker Payment for Cashless Exercise as the stated method on 03/09/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/09/2026 - 05:24 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001835458
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Kiniksa Pharmaceuticals International, plc
SEC File Number	001-38492
Address of Issuer	105 PICCADILLY, SECOND FLOOR LONDON UNITED KINGDOM W1J 7NJ
Phone	7814319100
Name of Person for Whose Account the Securities are To Be Sold	Ragosa Mark
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A ordinary shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	36722	1686179.00	45900637	03/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A ordinary shares	03/09/2026	Employee Stock Option Exercise	Kiniksa Pharmaceuticals, Ltd.			36722	03/09/2026	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mark Ragosa 105 PICCADILLY, SECOND FLOOR LONDON X0 W1J 7NJ	Kiniksa Pharmaceuticals International, plc	01/08/2026	12000	502628.00
Mark Ragosa 105 PICCADILLY, SECOND FLOOR LONDON X0 W1J 7NJ	Kiniksa Pharmaceuticals International, plc	02/09/2026	17845	772311.00

144: Remarks and Signature

Remarks
Date of Notice	03/09/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/14/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Mark Ragosa
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)